Gene · 5817
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Construction and validation of a prognostic model based on mitochondria-associated endoplasmic reticulum membranes gene signature in LUAD patients. | PLoS One | 2025 | 40953006 | PubTator, text mining | PubMed |
| Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine. | Cancer Med | 2025 | 40948290 | PubTator, text mining | PubMed |
| Impact of Precapillary Component of Pulmonary Pressure in Tricuspid Transcatheter Edge-to-Edge Repair: Results From TRI-SPA. | JACC Adv | 2025 | 40945427 | PubTator, text mining | PubMed |
| Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy. | Korean J Clin Oncol | 2025 | 40916400 | PubTator, text mining | PubMed |
| HIV-1 manipulates CD96 on CD4+ T cells to subvert antiviral immunity. | Sci Adv | 2025 | 40911682 | PubTator, text mining | PubMed |
| Integrated Single-Cell RNA-Seq Reveals Immunosuppressive Mechanisms of Treg Cell Differentiation and Tumor Microenvironment Interactions in Colorectal Cancer. | Cancer Med | 2025 | 40891683 | PubTator, text mining | PubMed |
| TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies. | Cell Death Dis | 2025 | 40890162 | PubTator, text mining | PubMed |
| An Epigenetic Nanoagonist Facilitates T Cell Priming, Recruitment, and Reinvigoration in Tumors Resistant to PD-L1 Therapy. | Adv Mater | 2025 | 40883972 | PubTator, text mining | PubMed |
| The Interface of Gene Editing with Regenerative Medicine. | Engineering (Beijing) | 2025 | 40881775 | PubTator, text mining | PubMed |
| PD-1+ NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade. | J Exp Clin Cancer Res | 2025 | 40877861 | PubTator, text mining | PubMed |
| Differential Immune Checkpoint Expression in CD4+ and CD4- NKT Cell Populations During Healthy Pregnancy. | Int J Mol Sci | 2025 | 40869342 | PubTator, text mining | PubMed |
| Electrophysiological Substrate and Pulmonary Vein Reconnection Patterns in Recurrent Atrial Fibrillation: Comparing Thermal Strategies in Patients Undergoing Redo Ablation. | J Cardiovasc Dev Dis | 2025 | 40863364 | PubTator, text mining | PubMed |
| SLAMF1 expression in breast cancer cells delays tumor growth in vivo. | Sci Rep | 2025 | 40855211 | PubTator, text mining | PubMed |
| Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression. | Discov Oncol | 2025 | 40853435 | PubTator, text mining | PubMed |
| Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review). | Int J Mol Med | 2025 | 40849827 | PubTator, text mining | PubMed |
| Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances. | J Exp Clin Cancer Res | 2025 | 40849493 | PubTator, text mining | PubMed |
| Clinical applications of circulating tumor cells in metastasis and therapy. | J Hematol Oncol | 2025 | 40846962 | PubTator, text mining | PubMed |
| Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B. | BMC Cancer | 2025 | 40841937 | PubTator, text mining | PubMed |
| Pathophysiology of endothelial dysfunction in Fontan circulation: from bench to bedside and back again. | Angiogenesis | 2025 | 40841590 | PubTator, text mining | PubMed |
| First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study. | Signal Transduct Target Ther | 2025 | 40835595 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5817/papers?page=12